13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001931118
Total reported value
$158.4M
$158.4M
34 檔
21.2%
As reported in its official Q1 2025 Form 13F filing, Superstring Capital Management LP's tracked investment portfolio stood at $158.4M with 34 total positions.
During Q1 2025, Superstring Capital Management LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including ZLAB, BBIO, VRNA) accounted for 21.2% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 12.68% | -1.84% | -26.93% | |
| 2 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 7.56% | — | -29.84% | |
| 3 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 7.31% | — | — | |
| 4 | LEGN | Legend Biotech Corp-adr | Stock-Other | 6.48% | — | +130.54% | |
| 5 | PFE | Pfizer Inc | Stock-Healthcare | 5.91% | -1.48% | EXIT | |
| 6 | URGN | UroGen Pharma Ltd. | Stock-Other | 5.57% | -0.53% | +40.65% | |
| 7 | COGT | Cogent Biosciences Inc | Stock-Other | 5.52% | +2.20% | -14.95% | |
| 8 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 5.44% | +1.74% | -54.00% | |
| 9 | TVTX | Travere Therapeutics Inc | Stock-Other | 5.06% | -2.18% | EXIT | |
| 10 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 4.46% | — | -32.83% | |
| 11 | CYTK | Cytokinetics Inc | Stock-Healthcare | 3.49% | — | -43.59% | |
| 12 | SVRA | Savara Inc | Stock-Other | 3.18% | -2.39% | +90.07% | |
| 13 | SMMT | Summit Therapeutics Inc | Stock-Other | 3.03% | -12.09% | EXIT | |
| 14 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 2.85% | — | — | |
| 15 | CAPR | Capricor Therapeutics Inc | Stock-Other | 2.72% | — | +336.71% | |
| 16 | VSTM | Verastem Inc | Stock-Other | 2.41% | — | +60.26% | |
| 17 | TARA | Protara Therapeutic Inc | Stock-Other | 1.82% | -0.16% | — | |
| 18 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.74% | — | — | |
| 19 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.64% | — | — | |
| 20 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.50% | — | +237.91% | |
| 21 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.49% | — | — | |
| 22 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.25% | -0.82% | EXIT | |
| 23 | TECX | Tectonic Therapeutic Inc | Stock-Other | 1.07% | — | — | |
| 24 | ZBIO | Zenas Biopharma Inc | Stock-Other | 1.05% | — | — | |
| 25 | ETNBGBP | 89bio Inc | Stock-Other | 0.94% | — | -17.92% | |
| 26 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.78% | — | — | |
| 27 | CABA | Cabaletta Bio Inc | Stock-Other | 0.76% | +0.15% | -44.18% | |
| 28 | PCVX | Vaxcyte Inc | Stock-Other | 0.51% | -2.14% | — | |
| 29 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.44% | — | +5.00% | |
| 30 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.37% | — | — | |
| 31 | SDGR | Schrodinger Inc | Stock-Other | 0.33% | — | — | |
| 32 | IPSC | Century Therapeutics Inc | Stock-Other | 0.26% | -0.19% | EXIT | |
| 33 | CPIX | Cumberland Pharmaceuticals | Stock-Other | 0.25% | — | — | |
| 34 | ✓ | Stock-Other | 0.09% | — | — |
According to official SEC Form 13F filings, Superstring Capital Management LP reported a total U.S. public equity portfolio value of $158.4M across 34 disclosed positions in Q1 2025.
During Q1 2025, Superstring Capital Management LP's top holdings by market value included ZLAB (12.7%)、BBIO (7.6%)、VRNA (7.3%). The largest single position, ZLAB, represented 12.7% of total portfolio value.
In Q1 2025, Superstring Capital Management LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.